Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease

Kidney International

Volumn 94, Issue 2, 2018, Pages 315-325

  Durlacher Betzer, Karina ^a   Hassan, Alia ^a   Levi, Ronen ^a   Axelrod, Jonathan ^a   Silver, Justin ^a   Naveh Many, Tally ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

chronic inflammation; cytokines; mineral metabolism; osteoblasts; STAT3

Indexed keywords

DEXAMETHASONE; FIBROBLAST GROWTH FACTOR 23; INTERLEUKIN 6; MESSENGER RNA; STAT3 PROTEIN; ADENINE; FIBROBLAST GROWTH FACTOR; FOLIC ACID; FUSION PROTEIN; GLUCOCORTICOID; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN-6, MOUSE; STAT3 PROTEIN, MOUSE;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CALVARIA; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; HEK293 CELL LINE; HELA CELL LINE; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MC3T3 CELL LINE; MOLECULAR PATHOLOGY; MOUSE; MRNA EXPRESSION LEVEL; NEWBORN; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UMR-106 CELL LINE; UREMIA; WILD TYPE MOUSE; ANIMAL; BLOOD; BONE; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IMMUNOLOGY; KIDNEY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROMOTER REGION;

ACUTE KIDNEY INJURY; ADENINE; ANIMALS; BONE AND BONES; DEXAMETHASONE; DISEASE MODELS, ANIMAL; FIBROBLAST GROWTH FACTORS; FOLIC ACID; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; KIDNEY; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; RECEPTORS, INTERLEUKIN-6; RECOMBINANT FUSION PROTEINS; RENAL INSUFFICIENCY, CHRONIC; RNA, MESSENGER; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 85047762467     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2018.02.026     Document Type: Article

References (53)

1. Gutierrez, O.M., Mannstadt, M., Isakova, T., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359 (2008), 584–592.
2. Isakova, T., Cai, X., Lee, J., et al. Longitudinal FGF23 trajectories and mortality in patients with CKD. J Am Soc Nephrol 29 (2018), 579–590.
3. Prie, D., Urena, T.P., Friedlander, G., Latest findings in phosphate homeostasis. Kidney Int 75 (2009), 882–889.
4. Shimada, T., Kakitani, M., Yamazaki, Y., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113 (2004), 561–568.
5. Ben Dov, I.Z., Galitzer, H., Lavi-Moshayoff, V., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117 (2007), 4003–4008.
6. Krajisnik, T., Bjorklund, P., Marsell, R., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195 (2007), 125–131.
7. Canalejo, R., Canalejo, A., Martinez-Moreno, J.M., et al. FGF23 fails to inhibit uremic parathyroid glands. J Am Soc Nephrol 21 (2010), 1125–1135.
8. Galitzer, H., Ben Dov, I.Z., Silver, J., et al. Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease. Kidney Int 77 (2010), 211–218.
9. Komaba, H., Goto, S., Fujii, H., et al. Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77 (2010), 232–238.
10. White, K.E., Jonsson, K.B., Carn, G., et al. The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86 (2001), 497–500.
11. Kato, K., Jeanneau, C., Tarp, M.A., et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis - secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281 (2006), 18370–18377.
12. Lavi-Moshayoff, V., Wasserman, G., Meir, T., et al. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 299 (2010), F882–F889.
13. Silver, J., Naveh-Many, T., FGF-23 and secondary hyperparathyroidism in chronic kidney disease. Nat Rev Nephrol 9 (2013), 641–649.
14. Meir, T., Durlacher, K., Pan, Z., et al. Parathyroid hormone activates the orphan nuclear receptor Nurr1 to induce FGF23 transcription. Kidney Int 86 (2014), 1106–1115.
15. Hassan, A., Durlacher, K., Silver, J., et al. The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia. Am J Physiol Renal Physiol 310 (2015), F217–F221.
16. Nguyen-Yamamoto, L., Karaplis, A.C., St-Arnaud, R., et al. Fibroblast growth factor 23 regulation by systemic and local osteoblast-synthesized 1,25-dihydroxyvitamin D. J Am Soc Nephrol 28 (2017), 586–597.
17. Krieger, N.S., Culbertson, C.D., Kyker-Snowman, K., et al. Metabolic acidosis increases fibroblast growth factor 23 in neonatal mouse bone. Am J Physiol Renal Physiol 303 (2012), F431–F436.
18. Han, X., Xiao, Z., Quarles, L.D., Membrane and integrative nuclear fibroblastic growth factor receptor (FGFR) regulation of FGF-23. J Biol Chem 290 (2015), 10447–10459.
19. David, V., Martin, A., Isakova, T., et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89 (2016), 135–146.
20. Wolf, M., Koch, T.A., Bregman, D.B., Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 28 (2013), 1793–1803.
21. Hoke, T.S., Douglas, I.S., Klein, C.L., et al. Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. J Am Soc Nephrol 18 (2007), 155–164.
22. Mace, M.L., Gravesen, E., Hofman-Bang, J., et al. Key role of the kidney in the regulation of fibroblast growth factor 23. Kidney Int 88 (2015), 1304–1313.
23. Christov, M., Waikar, S.S., Pereira, R.C., et al. Plasma FGF23 levels increase rapidly after acute kidney injury. Kidney Int 84 (2013), 776–785.
24. Singh, S., Grabner, A., Yanucil, C., et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 90 (2016), 985–996.
25. Munoz Mendoza, J., Isakova, T., Ricardo, A.C., et al. Fibroblast growth factor 23 and inflammation in CKD. Clin J Am Soc Nephrol 7 (2012), 1155–1162.
26. Pereira, B.J.G., Shapiro, L., King, A.J., et al. Plasma levels of IL-1β TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int 45 (1994), 890–896.
27. Barreto, D.V., Barreto, F.C., Liabeuf, S., et al. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 77 (2010), 550–556.
28. Su, H., Lei, C.-T., Zhang, C., Interleukin-6 signaling pathway and its role in kidney disease: an update. Front Immunol, 8, 2017, 405.
29. Munoz Mendoza, J., Isakova, T., Cai, X., et al. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease. Kidney Int 91 (2017), 711–719.
30. Nechemia-Arbely, Y., Barkan, D., Pizov, G., et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol 19 (2008), 1106–1115.
31. Yoshino, J., Monkawa, T., Tsuji, M., et al. Leukemia inhibitory factor is involved in tubular regeneration after experimental acute renal failure. J Am Soc Nephrol 14 (2003), 3090–3101.
32. Lemay, S., Rabb, H., Postler, G., et al. Prominent and sustained up-regulation of gp130-signaling cytokines and the chemokine MIP-2 in murine renal ischemia-reperfusion injury. Transplantation 69 (2000), 959–963.
33. Gadient, R.A., Patterson, P.H., Leukemia inhibitory factor, interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury. Stem Cells 17 (1999), 127–137.
34. Senn, J.J., Klover, P.J., Nowak, I.A., et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes, 51, 2002, 3391.
35. Levy, D.E., Darnell, J.E., STATs: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3 (2002), 651–662.
36. Heinrich, P.C., Behrmann, I., Haan, S., et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374 (2003), 1–20.
37. Rose-John, S., IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8 (2012), 1237–1247.
38. Jones, S.A., Horiuchi, S., Topley, N., et al. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J 15 (2001), 43–58.
39. Martin, T.J., Sims, N.A., Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11 (2005), 76–81.
40. Shilo, V., Ben Dov, I.Z., Nechama, M., et al. Parathyroid-specific deletion of dicer-dependent microRNAs abrogates the response of the parathyroid to acute and chronic hypocalcemia and uremia. FASEB J 29 (2015), 3964–3976.
41. Kaludjerovic, J., Komaba, H., Sato, T., et al. Klotho expression in long bones regulates FGF23 production during renal failure. FASEB J 31 (2017), 2050–2064.
42. Yoshiko, Y., Wang, H., Minamizaki, T., et al. Mineralized tissue cells are a principal source of FGF23. Bone 40 (2007), 1565–1573.
43. Mace, M.L., Gravesen, E., Nordholm, A., et al. Kidney fibroblast growth factor 23 does not contribute to elevation of its circulating levels in uremia. Kidney Int 92 (2017), 165–178.
44. Jia, T., Olauson, H., Lindberg, K., et al. A novel model of adenine-induced tubulointerstitial nephropathy in mice. BMC Nephrol, 14, 2013, 116.
45. Angeletti, R.H., D'Amico, T., Ashok, S., et al. The chemokine interleukin-8 regulates parathyroid secretion. J Bone Miner Res 13 (1998), 1232–1237.
46. Rodriguez-Ortiz, M.E., Lopez, I., Munoz-Castaneda, J.R., et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 23 (2012), 1190–1197.
47. Liu, F., Song, Y., Liu, D., Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6 (1999), 1258–1266.
48. David, V., Francis, C., Babitt, J.L., Ironing out the cross talk between FGF23 and inflammation. Am J Physiol Renal Physiol 312 (2017), F1–F8.
49. Rossaint, J., Oehmichen, J., Van Aken, H., et al. FGF23 signaling impairs neutrophil recruitment and host defense during CKD. J Clin Invest 126 (2016), 962–974.
50. Rocksén, D., Lilliehöök, B., Larsson, R., et al. Differential anti-inflammatory and anti-oxidative effects of dexamethasone and N-acetylcysteine in endotoxin-induced lung inflammation. Clin Exp Immunol 122 (2000), 249–256.
51. Volovelsky, O., Cohen, G., Kenig, A., et al. Phosphorylation of ribosomal protein S6 mediates mammalian target of rapamycin complex 1-induced parathyroid cell proliferation in secondary hyperparathyroidism. J Am Soc Nephrol 27 (2016), 1091–1101.
52. Febvre-James, M., Bruyere, A., Le Vee, M., et al. The JAK1/2 inhibitor ruxolitinib reverses interleukin-6-mediated suppression of drug detoxifying proteins in cultured human hepatocytes. Drug Metab Dispos 46 (2018), 131–140.
53. Liu, S., Tang, W., Zhou, J., et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17 (2006), 1305–1315.